A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT05180799. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Study identification
- NCT ID
- NCT05180799
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 320 participants
Conditions and interventions
Interventions
- BA3071 Biological
- Nivolumab Biological
- Pembrolizumab Biological
- Pemetrexed (Alimta) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2022 (Actual)
- Primary completion
- Mar 19, 2025 (Actual)
- Completion
- Jun 30, 2026 (Estimated)
- Last update posted
- Jun 15, 2025
2022 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Piedmont West | Atlanta | Georgia | 30318 | — |
| Northwest Cancer Centers | Dyer | Indiana | 46311 | — |
| Morristown Medical Center/Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Icahn School of Medicine at Mt. Sinai | New York | New York | 10029 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05180799, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2025 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05180799 live on ClinicalTrials.gov.